NeuroQure

Executive Summary

NeuroQure is a Cambridge-based biotechnology company developing ASD Insight™, a first-of-its-kind diagnostic test for early autism spectrum disorder (ASD) risk detection. By analyzing a skin sample for a biophysical marker related to calcium signaling dysfunction, the test aims to identify ASD risk years before behavioral symptoms emerge, enabling earlier intervention and improved outcomes. Founded in 2020, the company addresses a critical unmet need in pediatric diagnostics, where objective biological tests for ASD are lacking. With a strong scientific foundation and a novel approach, NeuroQure is positioned to transform early autism diagnosis and intervention, potentially reducing long-term healthcare costs and improving quality of life for affected individuals and families.

Upcoming Catalysts (preview)

• Q3 2026FDA Breakthrough Device Designation or 510(k) Clearance60% success
• Q1 2027Publication of Clinical Validation Study Results in Peer-Reviewed Journal70% success
• Q4 2026Strategic Partnership with Major Pediatric Hospital or Diagnostic Lab50% success